{'fraction_non_alphanumeric': 0.03838771593090211, 'fraction_numerical': 0.007677543186180422, 'mean_word_length': 6.909090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Atorvastatin reduces platelet‐oxidized‐LDL receptor expression in hypercholesterolaemic patients

Background  Oxidized‐LDL (ox‐LDL) are proatherogenic and platelet‐activating molecules. Atorvastatin reduces platelet activity before cholesterol‐lowering action. CD36 and lectin‐like oxidized‐LDL receptor‐1 (LOX‐1) are specific ox‐LDL receptors expressed also in platelets. This study was planned to address whether the possible rapid effect of atorvastatin on platelets could be related to modulation of ox‐LDL receptors.